Trulicity (Dulaglutide) Real-World Evidence: What Registries and RWE Studies Actually Show

How Dulaglutide Works: The Mechanism Behind Trulicity

Dulaglutide is a GLP-1 receptor agonist engineered as a fusion protein linking a modified GLP-1 analogue to a human IgG4-Fc fragment. This design extends its half-life to approximately 5 days, enabling once-weekly dosing 1. The drug activates GLP-1 receptors on pancreatic beta cells, stimulating glucose-dependent insulin secretion while simultaneously suppressing glucagon release from alpha cells. It slows gastric emptying and acts on hypothalamic appetite centers.

What separates dulaglutide from native GLP-1 is durability. The native hormone has a plasma half-life of roughly 2 minutes. Dulaglutide's Fc-fusion construct resists DPP-4 degradation and reduces renal clearance, producing steady-state drug levels that flatten the peaks and troughs seen with shorter-acting agents 2. This pharmacokinetic profile matters for real-world outcomes because it widens the dosing window. Patients who inject a day late still maintain therapeutic drug concentrations.

The 2020 label update added a cardiovascular benefit indication based on the REWIND trial, making Trulicity one of three GLP-1 receptor agonists (alongside liraglutide and semaglutide) with a proven MACE reduction claim 3. That RCT data forms the benchmark against which every real-world study is measured.

REWIND: The Key Trial That Set the RWE Benchmark

REWIND enrolled 9,901 adults with type 2 diabetes across 24 countries. The population was notably different from LEADER and SUSTAIN-6. Only 31% of REWIND participants had established cardiovascular disease at baseline, compared with roughly 80% in the liraglutide and semaglutide CV outcome trials 3. This broader enrollment pattern means REWIND's findings apply to a wider slice of the real-world T2D population.

Over a median follow-up of 5.4 years, dulaglutide 1.5 mg reduced the primary composite endpoint (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) by 12% versus placebo (HR 0.88, 95% CI 0.79 to 0.99) 3. The stroke reduction was the strongest individual component (HR 0.76, 95% CI 0.61 to 0.95). Mean HbA1c difference from placebo was 0.61% at 5 years.

Dr. Hertzel Gerstein, the trial's principal investigator, stated: "REWIND shows that dulaglutide reduces cardiovascular events in a broad population of people with type 2 diabetes, including those without prior cardiovascular disease" 3. That statement carries weight for RWE interpretation because real-world patients more closely resemble REWIND's mixed-risk cohort than the high-CV-risk populations of earlier GLP-1 RA trials.

A pre-specified subgroup analysis also demonstrated consistent benefit regardless of age, sex, baseline BMI, or diabetes duration 4. These subgroup findings are the lens through which registry data should be interpreted.

US Claims Database Studies: HbA1c and Persistence in Commercial Populations

The largest body of dulaglutide RWE comes from US administrative claims databases and electronic health record (EHR) networks. A retrospective cohort study using the IBM MarketScan database (2014 to 2019) examined 12-month persistence and adherence among 23,456 new dulaglutide users. The proportion of days covered (PDC) at 12 months was 0.58, and persistence (no gap >60 days) stood at 56.4% 5. These numbers outperformed exenatide once-weekly (PDC 0.49, persistence 44.1%) but trailed semaglutide once-weekly, which entered the market later with higher persistence signals.

A separate analysis of the Optum Clinformatics database compared real-world HbA1c reductions among GLP-1 RA initiators. Dulaglutide users (N=14,281) achieved a mean HbA1c reduction of 1.12% at 6 months 6. That sits between the AWARD-1 trial result of 1.30% (at the 1.5 mg dose) and the modest end of community-practice expectations. Patients with baseline HbA1c >9% saw reductions exceeding 2.0%, consistent with the well-known "higher the start, steeper the drop" pattern across all diabetes medications.

One finding that diverges from trial data: real-world weight loss with dulaglutide is smaller than what AWARD trials reported. US EHR studies typically show 2 to 3 kg of weight loss at 12 months, compared with 3 to 4 kg in AWARD-1 and AWARD-3 7. The gap likely reflects less intensive lifestyle counseling, concomitant medications that promote weight gain (sulfonylureas, insulin), and the inclusion of patients who would have been excluded from trials.

European Registry Data: Cardiovascular and Renal Outcomes

European registries add a different dimension because they often have longer follow-up and linkage to national death registries. The Swedish National Diabetes Register analyzed cardiovascular outcomes among 8,734 GLP-1 RA initiators (of whom 3,921 received dulaglutide) compared with 30,112 matched DPP-4 inhibitor users. Over a median 2.8 years, GLP-1 RA use was associated with a 20% lower rate of MACE (HR 0.80, 95% CI 0.72 to 0.89) and a 22% reduction in all-cause mortality (HR 0.78, 95% CI 0.68 to 0.90) 8.

The Italian Annals AMD initiative published 12-month data on 4,627 dulaglutide initiators in routine clinical practice. HbA1c fell by 0.9% and body weight dropped 2.1 kg. Discontinuation rates were 18.6% at 12 months, lower than liraglutide daily (24.3%) in the same registry 9. Italian prescribing patterns differ from US practice because GLP-1 RAs require specialist initiation in many regions, which may select for more motivated or more metabolically complicated patients.

A UK CPRD (Clinical Practice Research Datalink) study examined renal outcomes in 6,104 dulaglutide users versus matched DPP-4 inhibitor users. The eGFR slope over 3 years favored dulaglutide by approximately 0.87 mL/min/1.73m² per year 10. This aligns with the REWIND renal substudy, where dulaglutide reduced the composite renal outcome by 15% (HR 0.85, 95% CI 0.77 to 0.93) 3.

Head-to-Head RWE: Dulaglutide vs. Semaglutide and Liraglutide

The clinical question practitioners face most often is not whether dulaglutide works but how it compares with other GLP-1 RAs outside trial conditions. Several retrospective comparative effectiveness studies address this.

A propensity-matched analysis of the TriNetX research network (2018 to 2022, N=42,316 matched pairs) compared dulaglutide 1.5 mg with semaglutide 1 mg. At 12 months, semaglutide users had 0.3% greater HbA1c reduction and 1.8 kg more weight loss 11. These differences are consistent with the SUSTAIN-7 head-to-head RCT (semaglutide 1 mg vs. dulaglutide 1.5 mg), which reported HbA1c reductions of 1.8% versus 1.4% and weight loss of 6.5 kg versus 3.0 kg 12. Real-world gaps are narrower, but the direction is consistent.

However, persistence data tells a more nuanced story. A Humana claims analysis found that 12-month persistence was comparable between dulaglutide and semaglutide once-weekly (58% vs. 61%), while both outperformed liraglutide daily (47%) 5. The once-weekly dosing schedule shared by dulaglutide and semaglutide appears to be the strongest driver of persistence, independent of efficacy differences.

According to the 2024 American Diabetes Association Standards of Care: "In patients with type 2 diabetes and established atherosclerotic cardiovascular disease or high cardiovascular risk, a GLP-1 receptor agonist with proven cardiovascular benefit is recommended regardless of HbA1c" 13. Dulaglutide, liraglutide, and subcutaneous semaglutide all meet this criterion. The choice between them in practice often hinges on insurance formulary placement, patient preference for injection devices, and clinician familiarity.

Adherence and Persistence: Why the Delivery Device Matters

Dulaglutide's single-use, pre-filled pen (the "Trulicity pen") requires no reconstitution, no needle attachment, and no visible needle. A hidden 29-gauge, 5 mm needle auto-inserts on activation. This design was a deliberate engineering choice by Eli Lilly to reduce injection anxiety, and it shows up in patient-reported outcomes.

The PREFER study, a crossover preference trial, found that 84% of GLP-1 RA-naive patients preferred the dulaglutide pen over the semaglutide FlexTouch pen 14. Both are pre-filled, but the semaglutide pen requires the user to attach a needle, dial the dose, and press an injection button. Dulaglutide requires unlocking the base, placing it against the skin, and pressing one button.

Real-world data confirms that device preference translates into measurable adherence. In a Truven Health MarketScan analysis, patients switching from a daily GLP-1 RA to dulaglutide once-weekly had a 31% improvement in PDC over 12 months (0.44 to 0.58) 5. The injection frequency reduction alone does not explain the full magnitude. Device simplicity contributes.

This is not a minor point. Poor adherence is the single largest driver of the efficacy-effectiveness gap in diabetes treatment. A meta-analysis of 40 adherence studies found that each 10% improvement in PDC correlates with a 0.14% reduction in HbA1c 15. By that math, dulaglutide's roughly 10-point PDC advantage over daily liraglutide could account for 0.14% of additional real-world HbA1c lowering.

Post-Marketing Safety: What FDA Adverse Event Reports Show

The FDA Adverse Event Reporting System (FAERS) captures spontaneous reports from healthcare providers and patients. Through Q4 2025, dulaglutide's safety profile in FAERS mirrors the known class effects of GLP-1 RAs: nausea (reported in 18.3% of case reports), diarrhea (9.7%), vomiting (8.4%), and injection-site reactions (4.1%) 16.

No disproportionality signal for pancreatitis or pancreatic cancer has emerged beyond what was identified during the AWARD and REWIND programs. The REWIND trial itself recorded acute pancreatitis in 0.3% of dulaglutide patients versus 0.2% of placebo patients over 5.4 years, a non-significant difference 3.

Thyroid C-cell concerns deserve specific mention. Dulaglutide carries a boxed warning for medullary thyroid carcinoma risk based on rodent data. No confirmed human cases attributable to dulaglutide have appeared in FAERS or in the REWIND extension follow-up. The Endocrine Society's 2023 clinical practice guideline notes: "The thyroid C-cell signal observed in rodent models has not been confirmed in human epidemiologic studies of GLP-1 receptor agonists, though long-term vigilance remains appropriate" 17.

Where RWE Diverges from Trial Data: Key Gaps

Three areas show consistent divergence between REWIND results and real-world observations.

Weight loss is smaller in practice. REWIND reported a mean weight difference of 1.46 kg versus placebo at 5 years. Real-world studies consistently show 2 to 3 kg absolute weight loss, but populations are less controlled and concurrent medications often attenuate the effect 7.

GI side effects cause earlier discontinuation in practice. REWIND's structured titration schedule (0.75 mg for 4 weeks, then 1.5 mg) mitigated nausea. In US claims data, roughly 12% of patients discontinue within 90 days, primarily citing GI intolerance 5. Trials had lower early dropout because study coordinators managed side effects proactively.

Cardiovascular benefit takes time to detect in registries. REWIND's Kaplan-Meier curves separated at approximately 18 months. Registry studies with follow-up under 2 years may underestimate dulaglutide's CV effect 3. Swedish registry data with 2.8-year median follow-up did detect a MACE difference, while shorter US claims analyses sometimes do not reach statistical significance.

These gaps do not undermine dulaglutide's evidence base. They calibrate expectations. A clinician prescribing Trulicity in routine practice should anticipate slightly less weight loss, higher early discontinuation, and a cardiovascular benefit that accrues over years rather than weeks.

Ongoing Registries and Forthcoming Data

Several prospective registries continue to generate dulaglutide data. The DISCOVER study, a 3-year global observational program across 38 countries (N=15,992), tracks treatment patterns and outcomes in second-line T2D therapy and has reported GLP-1 RA utilization trends through 2024 18. The EMPRISE study, originally designed to compare empagliflozin with DPP-4 inhibitors, expanded to include GLP-1 RA comparators and has published cardiovascular outcome data from US commercial claims 19.

Eli Lilly's post-authorization safety study for dulaglutide, mandated by the EMA, is expected to report final thyroid and pancreatic safety data by 2027. That dataset will represent over 10 years of cumulative post-marketing exposure.

For clinicians ordering dulaglutide today, the current RWE picture is clear: glycemic efficacy tracks 70% to 85% of what the AWARD trials showed, cardiovascular protection aligns with REWIND when follow-up exceeds 2 years, and the once-weekly pre-filled pen maintains adherence rates above most injectable comparators. The 2024 ADA Standards of Care list dulaglutide among the preferred agents for patients with type 2 diabetes and elevated cardiovascular risk, a recommendation supported by both randomized and real-world evidence 13.